FutureMeds is a network of modern dedicated research sites conducting clinical trials. We are able to find significant numbers of eligible patients for trials across a wide variety of therapy areas, thus helping pharmaceutical companies and contract research organisations to run clinical trials as efficiently and cost effectively as possible. Our priority is the safety and health of our patients and by helping to bring them future medicines today we can play a key part in improving health. We use innovative technologies to make clinical trials available for as many patients as possible by building their awareness of existing trials and simplifying their access to the latest medicine through the provision of home and virtual visits.
FutureMeds was founded by a team with unparalleled SMO experience and all our investigators are highly experienced in conducting general medicine clinical trials.
Meet The Team
Dr Radoslaw Janiak
Chief Executive Officer
Radoslaw studied medicine at the University of Warsaw graduating in 1997. After working as a hospital doctor for 4 years he moved into clinical research initially as a site director for a Polish CRO. Working for Synexus from 2005 until 2019 he was responsible for the rapid growth of the business across Central and Eastern Europe. He was appointed COO in 2015.
Chief Financial Officer
Marcin is a graduate in Economics from the University of Wroclaw. He spent 10 years working in senior finance roles for a number of multinational companies. He joined Synexus in 2012, initially as finance director for Central and Eastern Europe and has extensive knowledge of site operations, feasibility and contracting. Marcin was appointed as CFO of Synexus in 2017 and lead the integration of the European and US businesses.
Paul graduated from the University of Sheffield before training as a Chartered Accountant with KPMG. He spent five years in Practice before moving into industry. Formerly CFO of Synexus from 2010-2017, leading the business through a period of substantial growth culminating in two successful private equity exits. Paul is currently a non-executive director of The North West Fund.
If you would like to hear more about transforming your clinical trial process, please get in touch below.